RECURRENT WHO GRADE 2 GLIOMA
Clinical trials for RECURRENT WHO GRADE 2 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE 2 GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE 2 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for tough brain cancers
Disease control Recruiting nowThis phase 2 trial tests the drug erdafitinib in 30 adults with a specific type of brain tumor (IDH-wild type glioma) that has come back or is getting worse. The tumor must have a certain gene fusion (FGFR-TACC). Erdafitinib blocks a faulty protein that helps cancer cells grow. T…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo takes on recurrent glioblastoma
Disease control Recruiting nowThis early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC